| Not Yet Recruiting | 5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors NCT07404332 | Mohammed Milhem | Phase 1 |
| Recruiting | A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Ac NCT07213817 | Ipsen | Phase 1 / Phase 2 |
| Recruiting | Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors NCT06975410 | Yuhan Corporation | Phase 1 / Phase 2 |
| Recruiting | Phase III Clinical Study of VC004 in Patients With Localized Advanced/ Metastatic Solid Tumors NCT06658353 | Jiangsu vcare pharmaceutical technology co., LTD | Phase 3 |
| Recruiting | CD8 PET Imaging in Metastatic Solid Tumours NCT06534190 | University Medical Center Groningen | Phase 2 |
| Recruiting | Topical Tretinoin Prophylaxis for Anti-EGFR Induced Skin Toxicity in Patients With Solid Tumors NCT06358677 | University of Utah | Phase 2 |
| Recruiting | IBI3001 in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors NCT06349408 | Innovent Biologics (Suzhou) Co. Ltd. | Phase 1 |
| Terminated | A Dose-escalation, Dose-finding, and Expansion Study of XL495 in Participants With Locally Advanced or Metasta NCT06630247 | Exelixis | Phase 1 |
| Recruiting | ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor NCT06415487 | Acepodia Biotech, Inc. | Phase 1 |
| Recruiting | Lattice Radiotherapy for Dose-Escalated Palliation of Bulky Tumors NCT06416007 | University of Cincinnati | Phase 2 |
| Recruiting | A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1) NCT06521554 | Nuvalent Inc. | Phase 1 |
| Recruiting | A Dose Escalation and Expansion Study of [177Lu]Lu-SN201 in Participants With Advanced Cancer NCT06184035 | Spago Nanomedical AB | Phase 1 / Phase 2 |
| Active Not Recruiting | Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring NCT05919537 | Hummingbird Bioscience | Phase 1 |
| Recruiting | A Study on the Prevalence of Clinically Useful Mutations in Solid Tumor Characterized by Next Generation Seque NCT06028724 | Centro di Riferimento Oncologico - Aviano | — |
| Recruiting | Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors NCT05732831 | Tango Therapeutics, Inc. | Phase 1 / Phase 2 |
| Recruiting | FOG-001 in Locally Advanced or Metastatic Solid Tumors NCT05919264 | Parabilis Medicines, Inc. | Phase 1 / Phase 2 |
| Unknown | A Study of TY-2136b in Patients With Advanced Solid Tumors Harboring ALK, ROS1 or NTRK1-3 Alterations NCT05769075 | TYK Medicines, Inc | Phase 1 |
| Active Not Recruiting | A Study of ES014 in Patients With Locally Advanced or Metastatic Solid Tumours NCT05717348 | Elpiscience (Suzhou) Biopharma, Ltd. | Phase 1 |
| Active Not Recruiting | A First-in-Human, Phase 1 Study of TST003 in Subjects With Solid Tumors NCT05731271 | Suzhou Transcenta Therapeutics Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and NCT05378425 | Nectin Therapeutics Ltd | Phase 1 |
| Withdrawn | A Phase 1 Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of Repotrectinib in Advance NCT05828277 | Turning Point Therapeutics, Inc. | Phase 1 |
| Recruiting | A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrange NCT05384626 | Nuvalent Inc. | Phase 1 / Phase 2 |
| Unknown | A Study of Orally Administered JBI-802, an LSD1/HDAC6 Inhibitor, in Patients With Advanced Solid Tumors NCT05268666 | Jubilant Therapeutics Inc. | Phase 1 / Phase 2 |
| Unknown | SOX Combined With Sintilimab and Trastuzumab Versus SOX Regimen in the Perioperative Treatment of HER2-positiv NCT05218148 | Aiping Zhou | Phase 2 |
| Terminated | Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors NCT05275478 | Tango Therapeutics, Inc. | Phase 1 / Phase 2 |
| Terminated | Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors NCT05169437 | Tempus AI | Phase 2 |
| Active Not Recruiting | A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab NCT05081609 | Ascendis Pharma Oncology Division A/S | Phase 1 / Phase 2 |
| Recruiting | A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearra NCT05118789 | Nuvalent Inc. | Phase 1 / Phase 2 |
| Completed | A Study of RC118 in Patients With Locally Advanced Unresectable/Metastatic Solid Tumours NCT04914117 | RemeGen Co., Ltd. | Phase 1 |
| Unknown | A Study of CN202 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancie NCT05028478 | Curon Biopharmaceutical (Australia) Co Pty Ltd | Phase 1 / Phase 2 |
| Completed | Double/Triple Combinations of AN2025, AN0025 and Atezolizumab in Advanced Solid Tumors NCT04975958 | Adlai Nortye Biopharma Co., Ltd. | Phase 1 |
| Completed | Trial of XRD-0394, a Kinase Inhibitor, in Combination With Palliative Radiotherapy in Advanced Cancer Patients NCT05002140 | XRad Therapeutics Inc | Phase 1 |
| Terminated | A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid NCT04799054 | Ascendis Pharma Oncology Division A/S | Phase 1 / Phase 2 |
| Completed | A Retro-/Prospective, Non-interventional, Cohort Study in Adult Patients With Locally Advanced or Metastatic T NCT04814667 | Centre Leon Berard | — |
| Unknown | The Phase I/Phase II Clinical Study of VC004 in Patients With Localized Advanced/Metastatic Solid Tumors NCT04614740 | Jiangsu vcare pharmaceutical technology co., LTD | Phase 1 / Phase 2 |
| Completed | Advanced Lung Tumor Treated by Osimertinib Plus Anlotinib NCT04770688 | Shanghai Chest Hospital | Phase 1 / Phase 2 |
| Terminated | Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors NCT04383210 | Elevation Oncology | Phase 2 |
| Terminated | A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic NCT04260802 | Ocellaris Pharma, Inc. | Phase 1 / Phase 2 |
| Completed | ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors NCT04319757 | Acepodia Biotech, Inc. | Phase 1 |
| Completed | A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Adva NCT04200963 | Ikena Oncology | Phase 1 |
| Terminated | Phase 1/2 Study of OBI-999 in Patients With Advanced Solid Tumors NCT04084366 | OBI Pharma, Inc | Phase 1 / Phase 2 |
| Unknown | Efficacy of Perioperative Chemotherapy Plus PD-1 Antibody in the Locally Advanced Gastric Cancer NCT04250948 | Sun Yat-sen University | Phase 2 |
| Completed | QUILT-3.064: PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid Cancers NCT04050709 | ImmunityBio, Inc. | Phase 1 |
| Completed | Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors NCT03881488 | Compass Therapeutics | Phase 1 |
| Unknown | HM95573 in Combination With Either Cobimetinib or Cetuximab in Patients With Locally Advanced or Metastatic So NCT03284502 | Hanmi Pharmaceutical Company Limited | Phase 1 |
| Completed | Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors NCT01390818 | EMD Serono | Phase 1 |